Linagliptin should not be used in patients with Type I diabetes or for the treatment
of diabetic ketoacidosis, and has not been studied in combination with insulin.
Glyxambi is linagliptin and empagliflozin.
- TRADE NAMES: Glyxambi (Boehringer Ingelheim); Tradjenta (Boehringer Ingelheim)
- INDICATIONS: Type II diabetes mellitus
- CLASS: Antidiabetic, Dipeptidyl peptidase-4 (DPP-4) (gliptin) inhibitor
- HALF-LIFE: 12 hours
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE links (above) to see reviews of linagliptin in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
